BofA warns Fed risks policy mistake with early rate cuts
Investing.com - Tango Therapeutics reported on Thursday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Tango Therapeutics announced earnings per share of $-0.33 on revenue of $6.92M. Analysts polled by Investing.com EPS of $-0.34 on revenue of $5.56M.
Tango Therapeutics 's are down 4.96% and is trading at $7.40 , still down 48.29% from its 52 week high of $14.31 set on Tuesday, November 16, 2021.
Tango Therapeutics shares lost 2.50% to trade at $7.40 in intra-day trade the report.
Tango Therapeutics follows other major Healthcare sector earnings this month
Tango Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar